Ikena Oncology, Inc. provided an organizational update outlining key objectives toward advancing the development of its lead targeted oncology assets, IK-930 and IK-595. The company also announced an organizational streamlining that allows for the reallocation of resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs. These efforts reinforce the company's dedication to maximize impact and drive advancements in patient-directed treatments for cancer. IK-930: TEAD1-Selective Hippo Pathway Inhibitor: An optimized formulation is now being dosed in the clinic concurrently with the original formulation; The company has expanded and accelerated targeted recruitment of mesothelioma patients and additional epithelioid hemangioendothelioma (EHE) patients; A clinical data update is planned for the second half of 2024.

IK-595: MEK-RAF Molecular Glue: The initial cohort was dosed with IK-595 in December 2023 and has subsequently cleared the safety evaluation window; Enrollment of targeted RAS and RAF mutant cancer patients in dose escalation continues, where multiple dosing schedules are being explored; Backfill and expansion cohorts are planned in multiple indications where IK-595 may have differentiated advantages. Strategic and Corporate Updates: With the advancement of IK-930 and IK-595, the Company has made the strategic decision to reallocate resources from the discovery organization to the clinical programs; This includes a workforce reduction of approximately 35%, to be implemented over the course of the first quarter of 2024; With approximately $175 million in cash and cash equivalents as of December 31, 2023 (unaudited), and as a result of the organization changes the company?s runway is extended into the second half of 2026.